Ideaya Biosciences stock hits 52-week high at $39.28
Ideaya Biosciences Inc. stock has reached a 52-week high of $39.28, reflecting an 85.02% increase over the past year and a market capitalization of $3.73 billion. This surge follows a successful public offering raising $345 million and the initiation of a Phase 1 clinical trial for IDE892 in combination with IDE397 to treat MTAP-deleted solid tumors. Analysts maintain a "Market Outperform" rating with a high price target of $66, indicating strong investor confidence and future growth potential in the biosciences sector.
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion
IDEAYA Biosciences (IDYA) has been added to several Russell growth and small-cap indexes, increasing its visibility to institutional investors. This inclusion, however, does not alter the core investment risk that depends on successful clinical and regulatory outcomes for its oncology pipeline. The company remains unprofitable, relying on equity funding, and its valuation is tied to future drug approvals despite recent stock price rises.
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion
IDEAYA Biosciences (IDYA) has been included in several Russell growth and small-cap indexes, including the Russell 3000 and 2000, which is expected to increase its visibility among institutional investors. While this broad inclusion could boost trading liquidity and expand its shareholder base, the company's core investment risk remains dependent on successful clinical and regulatory outcomes for its targeted oncology pipeline. Investors are considering factors like its current unprofitability, recent capital raise, and upcoming lock-up expiry alongside its potential undervaluation.
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark
IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 2500 Growth Benchmark. The company, an oncology firm focused on developing therapies for cancer, saw its stock price increase by 1.97%. IDEAYA Biosciences engages in the discovery, development, and commercialization of transformative therapies, with product candidates targeting synthetic lethality and antibody-drug conjugates for solid tumor indications.
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J
This article provides financial information for IDEAYA Biosciences, Inc. (FWB:30J) on TradingView, specifically focusing on its enterprise value to EBIT forward. It lists various general financial and community features available on the platform for this company's stock.
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark
IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), a company focused on oncology therapies, has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion highlights the company's growth trajectory and its position within the small-cap market. The article also provides an overview of recent news, financial data, and analyst consensus for IDEAYA Biosciences.
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark
IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 3000E Growth Benchmark. This news, published on June 29, 2026, highlights the company's inclusion in a significant stock market index. IDEAYA Biosciences is a precision oncology company focused on developing therapies for cancer.
Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J
The article provides the "Price to sales forward" data for IDEAYA Biosciences, Inc. (FWB:30J) as listed on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial metric. The data is available through TradingView, which sources its information from ICE Data Services and FactSet.
Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA
This article provides financial data for IDEAYA Biosciences, Inc. (IDYA) focusing on its price to book forward ratio. It highlights the company's listing on the Nasdaq Stock Market under the Pharmaceuticals: Major category within Health Technology. The content also includes various financial and community features offered by TradingView alongside market data disclaimers.
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark
IDEAYA Biosciences, Inc. (NasdaqGS: IDYA) has been added to the Russell 2000 Growth Benchmark. The company, which specializes in oncology therapies, recently announced its CEO as Chairman of the Board and initiated a Phase 1/2 clinical study for pancreatic and lung cancers. This inclusion highlights IDEAYA's growth in the biotechnology and medical research sector.
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA
This article provides a brief mention of the "Enterprise value to EBIT forward" metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). It appears to be a stub or a section within a larger financial data platform like TradingView, designed to display key financial ratios for the company.
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA
This article focuses on the enterprise value to revenue forward metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). The content presented is a financial data point from TradingView, indicating a key valuation multiple for the company.
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J
The article provides a financial metric for IDEAYA Biosciences, Inc. (FWB:30J), specifically its enterprise value to revenue forward. It notes that this data was "Made by humans" and that the market was closed with no trades at the time of publication. The content appears to be a stub or a data point from a financial platform like TradingView.
Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J
This article focuses on the "Price to book forward" financial metric for IDEAYA Biosciences, Inc. (FWB:30J) on the Frankfurt Stock Exchange. It indicates no trades and a closed market at the time of publication. The page appears to be a financial data portal displaying an overview of the company's financials.
Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA
This article displays the "Price to sales forward" financial metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA) on TradingView. It shows that the market is currently closed with no trades. The core content highlights this specific financial data point for the company.
IDEAYA Biosciences, Inc. Actuals & Estimates (DUS:30J)
This article provides financial actuals and estimates for IDEAYA Biosciences, Inc. (30J) traded on the Dusseldorf Stock Exchange. It includes details such as analyst price targets, historical stock prices, earnings reports, revenue figures, net income, EBITDA, employee count, and dividend policy. The company's next earnings report is scheduled for August 11, 2026.
Press Release: IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) announced inducement grants to a new employee as part of a retention and hiring incentive. These grants, consisting of non-qualified stock options to purchase 30,000 shares of common stock, were approved by the Compensation Committee and meet Nasdaq Listing Rule 5635(c)(4) requirements. The options have an exercise price equal to the closing price on June 26, 2026, and vest over four years.
IDEAYA lures 4 new hires with 98,000 stock options
IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options for an aggregate of 98,000 common shares to four new employees. These inducement awards, approved by the Compensation Committee, are part of the company's 2023 Employment Inducement Incentive Award Plan, with an exercise price of $36.29 and a 10-year term, vesting over four years. This move aims to attract and retain talent in line with Nasdaq Listing Rule 5635(c)(4).
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced it granted non-qualified stock options for 98,000 shares to four new hires on June 25, 2026. These grants, made under the 2023 Employment Inducement Incentive Award Plan, serve as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price matching the closing stock price on the grant date and will vest over four years.
IDEAYA Biosciences, Inc. Actuals & Estimates (NASDAQ:IDYA)
This article provides an overview of IDEAYA Biosciences, Inc. (IDYA) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial estimates, and upcoming earnings reports, along with other key financial metrics and trading information. The company's stock has shown significant growth over the past year, and analysts have a wide range of price targets.
IDYA Forecast — Price Target — Prediction for 2027
This article provides an outlook on IDEAYA Biosciences, Inc. (IDYA) stock, including analyst price targets, past performance, and future forecasts. It details the company's financial metrics, earnings reports, and market capitalization, as well as answers frequently asked questions about the stock.
Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair
IDEAYA Biosciences held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders approved all three proposals, including the election of directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Following the meeting, the Board of Directors elected Yujiro S. Hata as Chairman and Terry Rosen, Ph.D., as Lead Independent Director. The company reported detailed voting results for each proposal.
IDEAYA Biosciences (IDYA) Is Up 13.2% After New MTAP Trial And Roche Collaboration - Has The Bull Case Changed?
IDEAYA Biosciences has seen a 13.2% stock increase following the enrollment of its first patient in a Phase 1 trial for IDE892 combined with IDE397 for MTAP-deleted solid tumors and a new collaboration with Roche. These developments deepen the company's focus on precision oncology for MTAP-deleted cancers, an area with no approved targeted therapies. While these are early-stage efforts, they subtly reshape IDEAYA's risk profile, concentrating more R&D on MTAP-deleted tumors despite the company remaining unprofitable.
IDEAYA Biosciences (IDYA) Is Up 13.2% After New MTAP Trial And Roche Collaboration - Has The Bull Case Changed?
IDEAYA Biosciences (IDYA) has seen its shares rise by 13.2% after initiating a Phase 1 trial for IDE892 and IDE397 in MTAP-deleted solid tumors and forming a clinical collaboration with Roche. These developments, along with leadership changes, deepen IDEAYA's focus on MTAP-deleted cancers. The company remains unprofitable, and while these are positive steps, its investment narrative heavily relies on the success of its MTAP-deletion precision-oncology platform and the upcoming NDA filing for darovasertib.
IDEAYA (IDYA) director receives grant of 20,000 stock options
IDEAYA Biosciences director Jeffrey Stein was granted stock options to acquire 20,000 shares of common stock at an exercise price of $30.57 per share, expiring on June 16, 2036. These options are equity-based compensation and will vest 100% on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, provided he remains on the board. The transaction is marked as neutral in sentiment and impact according to the filing summary.
IDEAYA (IDYA) director Scott Morrison receives grant of 20,000 stock options
IDEAYA Biosciences director Scott W. Morrison was granted 20,000 stock options for Common Stock, with an exercise price of $30.57 per share and an expiration date of June 16, 2036. This compensation-related award vests on the earlier of one year from the grant date or immediately before the next Annual Meeting, provided he remains on the Board. After this transaction, Morrison holds 20,000 derivative securities.
IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares
IDEAYA Biosciences director Malcolm Garret Hampton was granted 20,000 stock options with an exercise price of $30.57 per share, expiring June 16, 2036. These options will vest fully on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, provided he continues his board service. This transaction is classified as compensation rather than an open-market trade.
Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant
IDEAYA Biosciences director Catherine J. Mackey was granted a stock option for 20,000 shares of common stock with an exercise price of $30.57 per share, expiring on June 16, 2036. The options will vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, contingent on her continued service on the Board. This grant is classified as compensation for Board service rather than a market purchase.
IDEAYA Biosciences (IDYA) director receives stock options on 20,000 shares
IDEAYA Biosciences director Wendy L. Yarno received a grant of stock options for 20,000 shares of common stock with an exercise price of $30.57 per share. These options will vest 100% on the earlier of one year from the grant date or immediately before the next Annual Meeting, contingent on her continued service on the Board. The grant, documented in a Form 4 SEC filing, is a compensation-related equity award and not an open-market transaction.
IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57
IDEAYA Biosciences director Terry J. Rosen was granted 20,000 stock options at an exercise price of $30.57 per share, expiring on June 16, 2036. The options will vest 100% on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, provided he continues to serve on the Board. This grant is considered routine equity compensation and does not involve open-market transactions.
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IDEAYA Biosciences Inc (IDYA), highlighting its current price momentum score, trading range between support and resistance levels, and signals from various technical indicators. It also details the performance of moving averages, with a summary indicating strong buy signals for IDYA based on these metrics. The analysis suggests that while technical indicators point to a "Buy" signal, investors should consider this as part of a broader investment strategy.
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis
IDEAYA Biosciences Inc (IDYA) currently has a valuation score of 8.91, ranking 78th out of 388 in its industry. Its P/E ratio is -19.80, which is significantly lower than its recent high but above its recent low. The company has not yet disclosed relevant data for P/B, P/S, and P/CF ratios.
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates
IDEAYA Biosciences Inc (IDYA) has an earnings forecast score of 8.53, ranking 106th in the Biotechnology & Medical Research industry. Analysts have an average price target of $46.00 for IDYA, with most analysts recommending a "Buy" trend. The company's expected revenue for the next quarter is $5.19 million, and its previous quarter's EPS was -$0.94, with the next quarter's EPS expected at -$0.98.
IDEAYA Biosciences elects Yujiro S. Hata board chairman
IDEAYA Biosciences has appointed its President and CEO, Yujiro S. Hata, as Chairman of the Board, effective June 17, 2026. This move follows a $345 million public offering and aims to support commercial launch preparations and clinical pipeline advancements. Concurrently, independent director Terry Rosen, Ph.D., has been named Lead Independent Director.
IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman
IDEAYA Biosciences has announced that its CEO, Yujiro S. Hata, has been elected as the Chairman of the Board of Directors. Hata is the founder of IDEAYA Biosciences, established in 2015, and also holds directorial positions at other biotech companies. The company is actively involved in developing transformative cancer therapies, focusing on product candidates for solid tumor indications.
Ideaya Biosciences Announces Yujiro S. Hata Elected as Chairman of Board of Directors
IDEAYA Biosciences, Inc. announced that its Board of Directors has elected Yujiro S. Hata as Chairman of the Board. Mr. Hata currently serves as President, Chief Executive Officer, and a board member of IDEAYA. Terry Rosen, Ph.D., will assume the role of Lead Independent Director for the company's Board.
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
IDEAYA Biosciences, Inc. announced that its Board of Directors has elected Yujiro S. Hata as Chairman of the Board. Hata, currently the President and CEO, has been instrumental in the company's growth into a leading precision medicine oncology firm. Dr. Terry Rosen will now serve as Lead Independent Director.
IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial Milestone
IDEAYA Biosciences (IDYA) stock is gaining attention after enrolling the first patient in a Phase 1 trial for MTAP-deleted solid tumors. Despite trading at $30.57 and showing recent short-term momentum, its valuation presents a mixed picture: an internal fair value estimate suggests an 81.5% discount, while its 11.9x Price-to-Sales (P/S) ratio appears high compared to industry averages and an estimated fair P/S of 2.7x. The company, currently unprofitable, faces risks related to its losses and future trial outcomes, though its discounted cash flow model suggests a much higher fair value of $165.44.
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides details on IDEAYA Biosciences Inc's (IDYA) stock performance and a partial revenue breakdown. It notes that relevant data for business segments and regional revenue contributions have not been fully disclosed by the company yet, beyond mentioning a United States revenue of $218.71 million. The article includes current stock prices and market capitalization data for IDYA.
Is IDEAYA Biosciences (IDYA) Quietly Reframing Its MTAP Strategy With the New IDE892 Combinations?
IDEAYA Biosciences is expanding its precision oncology focus in MTAP-deleted cancers by initiating a Phase 1 trial for IDE892 in combination with IDE397 and collaborating with Roche to test IDE892 with a pan-RAS inhibitor. While these developments deepen the company's MTAP franchise, the primary investor catalyst remains the upcoming FDA review of darovasertib for metastatic uveal melanoma. The company's recent equity raise strengthens its balance sheet but also highlights ongoing dilution and execution risk associated with its expanding early-stage pipeline.
Ideaya Biosciences stock rises on phase 1/2 cancer trial start By Investing.com
Ideaya Biosciences Inc. (NASDAQ:IDYA) shares rose after the company announced the start of a phase 1 clinical trial for IDE892 in combination with IDE397 to treat MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. Preclinical studies showed promising anti-tumor activity. The company is also collaborating with Roche and advancing a third proprietary program for MTAP-deleted cancers.
IDEAYA Biosciences enrolls first patient in IDE892 Phase 1/2 trial
IDEAYA Biosciences has enrolled the first patient in its Phase 1/2 clinical trial for the combination of IDE892 and IDE397, targeting MTAP-deleted solid tumors, particularly pancreatic and non-small cell lung cancer. The company observed favorable CYP450 properties for IDE892 in monotherapy trials and anticipates starting the monotherapy expansion in Q3 2026. This advancement is supported by a strategic collaboration with Roche and the development of a new asset for CDKN2A deletions.
Ideaya begins trial of IDE892 combo in lung, pancreatic cancer
Ideaya Biosciences has initiated a Phase 1 clinical trial for IDE892 in combination with IDE397 to treat MTAP-deleted solid tumors, focusing on non-small cell lung cancer and pancreatic cancer. The company maintains a strong financial position with substantial cash reserves and a high current ratio, alongside a "Strong Buy" consensus rating from analysts. Ideaya is also pursuing other pipeline advancements, including a collaboration with Roche and a third program targeting CDKN2A, while recently completing a successful public offering to raise substantial gross proceeds.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated a Phase 1/2 clinical study for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor. This study evaluates IDE892 in combination with IDE397 in MTAP-deleted solid tumors, particularly pancreatic and non-small cell lung cancers, which currently lack approved therapies. The company is also collaborating with Roche on a combination study with a pan-RAS inhibitor and advancing a third program for MTAP-deleted cancers.
New drug combo targets MTAP-deleted pancreatic and lung cancers
IDEAYA Biosciences has initiated a Phase 1/2 clinical trial for IDE892, an MTA-cooperative PRMT5 inhibitor, in combination with IDE397, a MAT2A inhibitor, to treat MTAP-deleted pancreatic and non-small cell lung cancers. This trial aims to leverage the synthetic lethal vulnerability created by MTAP deletion. The company is also collaborating with Roche on a separate combination therapy and developing a third program targeting CDKN2A for MTAP-deleted solid tumors.
Ideaya Biosciences stock rises on phase 1/2 cancer trial start
Ideaya Biosciences (NASDAQ: IDYA) shares rose after the company announced the start of a phase 1 clinical trial for IDE892 combined with IDE397 to treat MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. Preclinical studies showed this combination produced anti-tumor activity even at lower doses than monotherapy. The company also initiated a collaboration with Roche and is advancing another proprietary program for MTAP-deleted cancers.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated a Phase 1/2 clinical study for IDE892, an MTA-cooperative PRMT5 inhibitor, in combination with IDE397 (a MAT2A inhibitor) for MTAP-deleted pancreatic and lung cancers. This study addresses a significant unmet need as MTAP deletion occurs in a high percentage of these cancers and there are no approved therapies. The company is also collaborating with Roche on a trial combining IDE892 with a pan-RAS inhibitor and advancing a third proprietary program targeting CDKN2A in MTAP-deleted solid tumors.
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates
IDEAYA Biosciences (IDYA) reported a first-quarter loss of $0.68 per share, which is wider than the Zacks Consensus Estimate but narrower than the previous year's loss. The company also missed revenue estimates for the quarter. Investors will be focused on the company's pipeline updates and product sales in upcoming reports.
IDEAYA Biosciences closes $345M public offering
IDEAYA Biosciences (NASDAQ: IDYA) has completed an underwritten public offering, raising approximately $345 million in gross proceeds. The offering included common stock and pre-funded warrants, with the total boosted by the full exercise of the underwriters' option. This capital raise further strengthens the company's financial position, which InvestingPro data already rated as "GOOD" with more cash than debt.
IDEAYA Biosciences prices $300M public offering of shares and pre-funded warrants at $27/share
IDEAYA Biosciences has priced a public offering to raise $300 million, consisting of common stock and pre-funded warrants. The shares and warrants are being offered at a price of $27 per share. This offering aims to generate significant capital for the company.
